Alpha Tau Medical Accepted into FDA TPLC Program
Ticker: DRTSW · Form: 6-K · Filed: Oct 21, 2024 · CIK: 1871321
| Field | Detail |
|---|---|
| Company | Alpha Tau Medical Ltd. (DRTSW) |
| Form Type | 6-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: FDA, regulatory-approval, medical-technology
TL;DR
FDA TPLC program acceptance for Alpha Tau's Alpha DaRT® for GBM patients - faster path to market?
AI Summary
On October 21, 2024, Alpha Tau Medical Ltd. announced its acceptance into the FDA's Total Product Life Cycle (TPLC) Advisory Program. This program aims to accelerate market access for Alpha DaRT® for patients suffering from recurrent Glioblastoma Multiforme.
Why It Matters
Acceptance into the FDA's TPLC program can expedite the regulatory review process, potentially bringing Alpha DaRT® to patients with recurrent Glioblastoma Multiforme sooner.
Risk Assessment
Risk Level: medium — While FDA acceptance is positive, the actual market access and commercial success of Alpha DaRT® are still subject to further regulatory steps and market adoption.
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — Registrant
- FDA (company) — Regulatory body
- Alpha DaRT® (product) — Medical technology
- Glioblastoma Multiforme (medical_condition) — Target disease
FAQ
What is the primary goal of Alpha Tau Medical's acceptance into the FDA's TPLC Advisory Program?
The primary goal is to accelerate market access for Alpha DaRT® for patients with recurrent Glioblastoma Multiforme.
What specific medical condition is Alpha DaRT® intended to treat in this context?
Alpha DaRT® is intended to treat recurrent Glioblastoma Multiforme.
On what date was this announcement made by Alpha Tau Medical Ltd.?
The announcement was made on October 21, 2024.
What form was filed with the SEC regarding this announcement?
A Form 6-K was filed with the SEC.
What does the TPLC Advisory Program aim to achieve for medical products?
The TPLC Advisory Program aims to accelerate the market access for medical products.
Filing Stats: 315 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-10-21 08:32:29
Filing Documents
- ea0218113-6k_alpha.htm (6-K) — 14KB
- ea021811301ex99-1_alpha.htm (EX-99.1) — 12KB
- 0001213900-24-089100.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: October 21, 2024 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 3